March 24, 2020 / 11:58 AM / 2 days ago

FACTBOX-Drugmakers rush to develop COVID-19 treatments

 (Updates Gilead, Regeneron, Roche, Glenmark)
    July 14 (Reuters) - Drugmakers around the world are rushing to develop treatments for COVID-19, the fast-spreading respiratory disease caused by the novel coronavirus
that has killed hundreds of thousands. Gilead Sciences Inc's remdesivir is at the forefront of the efforts to treat the disease, after it helped shorten hospital
recovery times in a clinical trial.
    The following is a list of major companies that are developing treatments. For a separate FACTBOX on vaccines under development, click here:
 Date of     Company                         Progress                                                                                      Development stage  Story link 
 July 10     Gilead Sciences Inc             Several countries, including Israel, have approved the emergency use of remdesivir. Analysis  Late-stage trial.              
                                             showed that the drug helped reduce risk of death in severely ill COVID-19 patients, but the                      
                                             company has warned that rigorous clinical trials are needed to confirm that benefit.                             
 June 9      AstraZeneca Plc                 Received $23.7 million in funding from a U.S. government agency to advance the development    Starting clinical              
                                             of antibody-based COVID-19 treatments.                                                        studies of two     
                                                                                                                                           therapies in the   
                                                                                                                                           next few months.   
 July 7      Regeneron Pharmaceuticals Inc   Has begun tests of its experimental antibody cocktail in humans. The U.S. government signed   Early-stage                    
                                             a $450 million contract for its potential COVID-19 antibody cocktail.                         trials.            
 July 8      Roche Holding AG                The Swiss drugmaker is pressing ahead with a trial of its rheumatoid arthritis drug Actmera   Enrollment in                  
                                             in COVID-19. The European Commission has reached agreement with Regeneron for supply of       late-stage study   
                                             experimental drugs that can be used to treat COVID-19 patients.                               began in April.    
 June 10     Eli Lilly                       Has begun early-stage trials for two of its antibody treatments.                              Results                        
                                                                                                                                           anticipated by     
                                                                                                                                           June end.          
 May 1       AbbVie Inc                      Israel has approved generic version of company's branded HIV drug Kaletra. Company has also   Early-stage                    
                                             initiated trial of cancer drug Imbruvica, which it jointly sells with J&J, in COVID-19        trials.            
 May 29      Vir Biotechnology Inc           Partnered with Biogen Inc          and Alnylam Pharmaceuticals Inc          for development   Plans to begin                 
                                             of potential coronavirus treatment.                                                           human trials by                
                                                                                                                                           end of year.       
 July 13     Glenmark Pharmaceuticals Ltd    Received Indian regulatory approval to make and sell favipiravir, a version of Fujifilm       Began a                        
                                             Holdings Corp's          antiviral drug Avigan, for treating mild-to-moderate COVID-19        late-stage trial   
                                             infections.                                                                                   in May. Glenmark   
                                                                                                                                           is separately      
                                                                                                                                           testing a          
                                                                                                                                           combination of     
                                                                                                                                           favipiravir and    
                                                                                                                                           anti-viral drug.   
 June 16     Not applicable                  A trial by researchers in the United Kingdom showed the steroid drug dexamethasone, made by   Trial ongoing in               
                                             several generic drugmakers, reduced death rates in hospitalized COVID-19 patients. Germany's  children.          
                                             Fresenius SE           has said it has enough supply of the drug at hand, and it would seek                      
                                             to increase supply to keep up sufficient deliveries.                                                             

 (Reporting by Manas Mishra and Trisha Roy in Bengaluru; Editing by Saumyadeb Chakrabarty and Arun Koyyur)
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below